347. Deputy Cathal Crowe asked the Minister for Health the status of price negotiations between the Health Service Executive Corporate Pharmaceutical Unit and the manufacturer regarding the reimbursement of omaveloxolone (skyclarys) for the treatment of Friedreich's ataxia; if she will address concerns regarding the omission of this life-altering therapy from the immediate agenda of the HSE Drugs Group ahead of the summer recess of Dáil Éireann; the steps she is taking to accelerate the reimbursement process for rare disease treatments in line with the National Rare Disease Strategy; and if she will make a statement on the matter. [44823/26]

Summary

347. Deputy Cathal Crowe asked the Minister for Health the status of price negotiations between the Health Service Executive Corporate Pharmaceutical Unit and the manufacturer regarding the reimbursement of omaveloxolone (skyclarys) for the treatment of Friedreich's ataxia; if she will address concerns regarding the omission of this life-altering therapy from the immediate agenda of the HSE Drugs Group ahead of the summer recess of Dáil Éireann; the steps she is taking to accelerate the reimbursement process for rare disease treatments in line with the National Rare Disease Strategy; and if she will make a statement on the matter. [44823/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 11 June 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.